Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.65 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.57 |
| ▸ | AXL | P30530 | 2/20 | 0.56 |
| ▸ | INSR | P06213 | 1/20 | 0.54 |
| ▸ | IGF1R | P08069 | 1/20 | 0.54 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.54 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.54 |
| ▸ | CCNK | O75909 | 1/20 | 0.54 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | CDK9 | P50750 | 1/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14981326 | 0.91 | LRRK2 (0.79) | LRRK2MAP3K9MKNK2 | |
| SCHEMBL10208085 | 0.88 | LRRK2 (0.62) | LRRK2ALKINSRIGF1RMAP3K9 | |
| SCHEMBL1911990 | 0.87 | ALK (0.68) | LRRK2ALKAXLINSRIGF1R | |
| SCHEMBL10208739 | 0.85 | ZAP70 (0.59) | LRRK2ALKINSRIGF1R | |
| SCHEMBL1911966 | 0.82 | ALK (0.62) | LRRK2ALKINSRIGF1RMAP3K9 | |
| SCHEMBL17244676 | 0.81 | ALK (0.57) | LRRK2ALKAXLINSRIGF1R | |
| SCHEMBL1911944 | 0.80 | LRRK2 (0.74) | LRRK2ALKINSRIGF1RMAP3K9 | |
| SCHEMBL1911954 | 0.80 | LRRK2 (0.65) | LRRK2ALKAXLINSRIGF1R | |
| SCHEMBL1912025 | 0.80 | LRRK2 (0.75) | LRRK2MAP3K9MKNK2 | |
| SCHEMBL14556271 | 0.80 | LRRK2 (0.86) | LRRK2MAP3K9MKNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2287156-B1 | 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2013-05-29 | — | — | EP | disclosed |